how much does noom glp 1 cost per month Noom and WeightWatchers both focus on behavioral weight loss. The Noom: Lose weight and keep

With key GLP-1 drug patents expected to expire around March 2026, Indian pharmaceutical companies are preparing to launch lower-cost alternatives in one of the fastest-growing therapeutic markets

G49, a dual glucagon/glucagon-like peptide-1 receptor agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas and liver, leading to brown fat activation with the final outcomes of increased energy expenditure and body weight loss.

Also, new information on treatments, dosage, and side effects.

Why This Matters: This isn't just a win for the industry

Future randomised controlled trials should specifically evaluate the effectiveness of novel AOMs for long-term weight management in older adults with obesity, carefully considering the impact on body composition and functional ability, as well as health economics.